PRNewsWire · October 27, 2026

Astellas and Audax Biosciences Enter Exclusive Option and License Agreement for DAX-044, a Novel Immune-Targeted IL-12 Antibody-Cytokine Fusion for Immuno-Oncology

Get the app for more

Explore stock news, insights and company research.